These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 33394998)
1. MONTHLY INTRAVITREAL INFLIXIMAB IN BEHÇET'S DISEASE ACTIVE POSTERIOR UVEITIS: A Long-Term Safety Study. Refaat M; Abdullatif AM; Hamza MM; Macky TA; El-Agha MH; Ragab G; Soliman MM Retina; 2021 Aug; 41(8):1739-1747. PubMed ID: 33394998 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients. Markomichelakis N; Delicha E; Masselos S; Sfikakis PP Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466 [TBL] [Abstract][Full Text] [Related]
4. Infliximab in the treatment of posterior uveitis in Behçet's disease. Long term follow up in four patients. Lanthier N; Parc C; Scavennec R; Dhôte R; Brézin AP; Guillevin L Presse Med; 2005 Jul; 34(13):916-8. PubMed ID: 16142147 [TBL] [Abstract][Full Text] [Related]
5. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab. Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238 [TBL] [Abstract][Full Text] [Related]
6. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions. Adán A; Hernandez V; Ortiz S; Molina JJ; Pelegrin L; Espinosa G; Sanmartí R Int Ophthalmol; 2010 Oct; 30(5):577-81. PubMed ID: 20490893 [TBL] [Abstract][Full Text] [Related]
7. Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Al Rashidi S; Al Fawaz A; Kangave D; Abu El-Asrar AM Ocul Immunol Inflamm; 2013 Dec; 21(6):468-74. PubMed ID: 23734940 [TBL] [Abstract][Full Text] [Related]
8. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years. Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325 [TBL] [Abstract][Full Text] [Related]
9. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304 [TBL] [Abstract][Full Text] [Related]
10. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease. Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481 [TBL] [Abstract][Full Text] [Related]
11. INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study. Hamza MM; Macky TA; Sidky MK; Ragab G; Soliman MM Retina; 2016 Dec; 36(12):2399-2408. PubMed ID: 27870802 [TBL] [Abstract][Full Text] [Related]
13. Methotrexate in ocular manifestations of Behcet's disease: a longitudinal study up to 15 years. Davatchi F; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Sadeghi Abdollahi B; Faezi T; Akhlaghi M; Ashofteh F Int J Rheum Dis; 2013 Oct; 16(5):568-77. PubMed ID: 24164845 [TBL] [Abstract][Full Text] [Related]